Short bowel syndrome
diseaseOn this page
Also known as short gut syndrome
Summary
Short bowel syndrome (MONDO:0015183) is a disease and 139 clinical trials. Top therapeutic interventions include teduglutide, fish oil triglycerides, and loperamide. A subtype of intestinal disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
- Clinical trials: 139
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-9 / 100 000 | 2 | Europe | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | short bowel syndrome |
| Mondo ID | MONDO:0015183 |
| MeSH | D012778 |
| Orphanet | 104008 |
| DOID | DOID:10605 |
| ICD-11 | 780637678 |
| NCIT | C99059 |
| SNOMED CT | 26629001 |
| UMLS | C0036992 |
| MedGen | 19966 |
| GARD | 0001502 |
| MedDRA | 10049416 |
| NORD | 1708 |
| Is cancer (heuristic) | no |
Also known as: short gut syndrome
Disease family
This is a subtype of intestinal disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › short bowel syndrome
Related subtypes (57): intestinal atresia, steatorrhea, angiodysplasia of intestine, endometriosis of intestine, hypertrophic pyloric stenosis, mucocele of appendix, gastroenteritis, diverticulitis, intestinal obstruction, postgastrectomy syndrome, chronic intestinal vascular insufficiency, bowel dysfunction, irritable bowel syndrome, Whipple disease, inflammatory bowel disease, intestinal polyp, necrotizing enterocolitis, intestinal perforation, neurogenic bowel, pneumatosis cystoides intestinalis, volvulus of midgut, abetalipoproteinemia, aplasia cutis congenita-intestinal lymphangiectasia syndrome, trichohepatoenteric syndrome, protein-losing enteropathy, chronic diarrhea with villous atrophy, Satoyoshi syndrome, glucose-galactose malabsorption, congenital diarrhea 7 with exudative enteropathy, chronic atrial and intestinal dysrhythmia, congenital enterocyte heparan sulfate deficiency, intractable diarrhea-choanal atresia-eye anomalies syndrome, solitary rectal ulcer syndrome, NK-cell enteropathy, chronic intestinal failure, intestinal lymphangiectasia, refractory celiac disease, eosinophilic gastrointestinal disease, cryptogenic multifocal ulcerous stenosing enteritis, chronic enteropathy associated with SLCO2A1 gene, cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder, malakoplakia, malabsorption syndrome, ischemic bowel disorder, intestinal neoplasm, intestinal motility disease, 4-hydroxyphenylacetic aciduria, parasitic intestinal disorder, Aeromonas hydrophila intestinal disease, large intestine disorder, small intestine disorder, primary desmosis coli, isolated mesenteric vein thrombosis, collagenous sprue, visceral leiomyopathy, African degenerative, intestinal dysmotility syndrome, intestinal fistula
Subtypes (1): secondary short bowel syndrome
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
3 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Glutamine | Approved (phase 4) |
| Somatropin | Approved (phase 4) |
| Teduglutide | Approved (phase 4) |
| FE 203799 | Phase 3 (in late-stage trials) |
| Glepaglutide | Phase 3 (in late-stage trials) |
| Opium | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Liraglutide, Tocofersolan.
Clinical trials & evidence
Clinical trials
Clinical trials: 139.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 71 |
| PHASE3 | 30 |
| PHASE2 | 15 |
| PHASE4 | 10 |
| PHASE1/PHASE2 | 4 |
| PHASE1 | 4 |
| PHASE2/PHASE3 | 3 |
| EARLY_PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00742157 | PHASE4 | TERMINATED | Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS) |
| NCT01380366 | PHASE4 | COMPLETED | rHGH and Intestinal Permeability in Intestinal Failure |
| NCT01818648 | PHASE4 | WITHDRAWN | Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome |
| NCT01974336 | PHASE4 | COMPLETED | The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Short Bowel Syndrome Patients |
| NCT02099084 | PHASE4 | COMPLETED | Short Bowel Syndrome and Teduglutide Versus Placebo |
| NCT02355743 | PHASE4 | COMPLETED | rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome |
| NCT02653131 | PHASE4 | TERMINATED | The Use of DPP-4 Inhibitors in Short Bowel Syndrome |
| NCT03054948 | PHASE4 | WITHDRAWN | SMOFLipid in Patients Who Are Intralipid Intolerant |
| NCT03562130 | PHASE4 | COMPLETED | Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients |
| NCT04344717 | PHASE4 | UNKNOWN | Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition |
| NCT03905707 | PHASE3 | ACTIVE_NOT_RECRUITING | Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS |
| NCT04881825 | PHASE3 | ACTIVE_NOT_RECRUITING | Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial |
| NCT05018286 | PHASE3 | ACTIVE_NOT_RECRUITING | Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. |
| NCT06512584 | PHASE3 | RECRUITING | Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition |
| NCT06973304 | PHASE3 | RECRUITING | A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome |
| NCT07197944 | PHASE3 | RECRUITING | Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS |
| NCT07228403 | PHASE3 | ENROLLING_BY_INVITATION | Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome |
| NCT00081458 | PHASE3 | COMPLETED | Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome |
| NCT00169637 | PHASE3 | COMPLETED | Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome |
| NCT00172185 | PHASE3 | COMPLETED | Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458) |
| NCT00798967 | PHASE3 | COMPLETED | Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects |
| NCT00910104 | PHASE2/PHASE3 | COMPLETED | Cholestasis Reversal: Efficacy of IV Fish Oil |
| NCT00930644 | PHASE3 | COMPLETED | Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS) |
| NCT01560403 | PHASE3 | COMPLETED | A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021 |
| NCT01952080 | PHASE3 | COMPLETED | A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome |
| NCT02242656 | PHASE3 | WITHDRAWN | A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals |
| NCT02246816 | PHASE3 | WITHDRAWN | A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001 |
| NCT02266849 | PHASE3 | TERMINATED | Loperamide vs. Placebo’s Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study |
| NCT02340819 | PHASE3 | COMPLETED | Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS) |
| NCT02370251 | PHASE2/PHASE3 | COMPLETED | Compassionate Use of Omegaven in Children |
| NCT02682381 | PHASE3 | COMPLETED | Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition |
| NCT02865122 | PHASE2/PHASE3 | TERMINATED | Safety and Efficacy Study in Infant With SBS |
| NCT02949362 | PHASE3 | COMPLETED | Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study |
| NCT02954458 | PHASE3 | COMPLETED | Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS) |
| NCT02980666 | PHASE3 | COMPLETED | Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support |
| NCT03268811 | PHASE3 | COMPLETED | A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302 |
| NCT03571516 | PHASE3 | COMPLETED | Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome |
| NCT03596164 | PHASE3 | COMPLETED | An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004 |
| NCT03663582 | PHASE3 | COMPLETED | Study of Teduglutide in Japanese Participants With Short Bowel Syndrome |
| NCT03690206 | PHASE3 | COMPLETED | Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS) |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| TEDUGLUTIDE | 4 | 24 |
| FISH OIL TRIGLYCERIDES | 4 | 3 |
| LOPERAMIDE | 4 | 3 |
| SOMATROPIN | 4 | 3 |
| URSODIOL | 4 | 2 |
| APIXABAN | 4 | 1 |
| CROFELEMER | 4 | 1 |
| EXENATIDE | 4 | 1 |
| FISH OIL | 4 | 1 |
| GLUTAMINE | 4 | 1 |
| OMEGA-3-ACID ETHYL ESTERS | 4 | 1 |
| SULFAMETHOXAZOLE | 4 | 1 |
| TOCOFERSOLAN | 4 | 1 |
| TRIMETHOPRIM | 4 | 1 |
| GLEPAGLUTIDE | 3 | 7 |
| FE 203799 | 3 | 3 |
| GLUCAGON-LIKE PEPTIDE II | 3 | 2 |
| ALANINE | 3 | 1 |
| CORN OIL | 3 | 1 |
| PECTIN | 3 | 1 |
| VUROLENATIDE | 2 | 2 |
| GUAR GUM | 2 | 1 |
| CHEMBL4439441 | 0 | 6 |
| CHEMBL5409583 | 0 | 1 |
| CHEMBL4127074 | 0 | 1 |